POM-V Prescription Required

Suvaxyn CSF Marker Lyophilisate and Solvent for Suspension for Injection for Pigs

Active ingredient: Classical Swine Fever E2 recombinant BVDV

Form

Injection

Species

Pigs

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5074

What it's used for

For active immunisation of pigs from 7 weeks of age onwards to prevent mortality and reduce infection and disease caused by classical swine fever virus (CS...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Classical Swine Fever E2 rec...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Suvaxyn CSF Marker Lyophilisate and Solvent for Suspension for Injection for Pigs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For active immunisation of pigs from 7 weeks of age onwards to prevent mortality
and reduce infection and disease caused by classical swine fever virus (CSFV).
Onset of immunity: 14 days
Duration of immunity: 6 months

Revised: March 2024
AN: 00274/2023
For active immunisation of breeding females to reduce transplacental infection
caused by CSFV.
Onset of immunity: 21days
Duration of immunity has not been established.

None.

Pigs:
Very Common (>1 animal / 10 animals
treated):
Injection site swelling
Common (1 to 10 animals / 100 animals
treated):
Elevated temperature
1
Transient, up to 5 mm in diameter and lasting for 1 day.
Transient, up to 2.9°C within 4 hours after vaccination and spontaneously resolving
within 1 day.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also section 16 of the
package leaflet for respective contact details.

Vaccinate healthy animals only.
Documentation provided for this vaccine supports that it is only to be used in an
outbreak situation in herds within restricted control zones.
Protection against transplacental transmission of CSFV was shown 21 days after
vaccination when challenge was applied in 6 pregnant sows with a moderately
virulent CSFV strain. Partial protection against transplacental transmission of CSFV
was observed when challenge was applied in 6 pregnant sows with a highly virulent
CSFV strain.
Birth of persistently infected immunotolerant piglets represent a very high risk since
they are shedding field virus and they cannot be identified serologically due to their
seronegative status. Vaccination of breeding animals may be included in risk-based
control strategies in case of outbreak and considering the above information.
The vaccine has shown reduced protection in studies of piglets with maternally
derived antibodies compared to studies of piglets without maternally derived
antibodies.
Studies in vaccinated breeding boars addressing potential shedding of virulent
challenge virus in semen have not been conducted. Use of the vaccine in
experimental studies in breeding boars has not revealed safety concerns.
Therefore, the decision to vaccinate breeding boars and piglets with maternally
derived antibodies should be taken based on the actual outbreak case and
associated control zones.
RT-PCR tools could be used in outbreak situations to differentiate between the
vaccine virus genome and those of field strains based on sequences unique to the
CP7_E2alf.

Special precautions for use in animals
Vaccine virus genome is rarely detectable by RT-PCR in tonsils and lymph nodes for
up to 63 days after vaccination and vaccine virus is very rarely detectable by virus
isolation in tonsil for the first week after vaccination. Transplacental transmission of
the vaccine virus has not been detected in the limited studies performed but cannot
be excluded.

Revised: March 2024
AN: 00274/2023
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
Other precautions
Not applicable.

No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case by
case basis.

Store and transport refrigerated (2 C – 8 C).
Do not freeze.
Protect from light.

Zero days.
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: live viral vaccines, live recombinant E2 gene-deleted
bovine viral diarrhoea virus containing classical swine fever virus E2 gene.
ATCvet Code: QI09AD04
To stimulate active immunity to classical swine fever virus.
The vaccine is a live recombinant E2 gene-deleted bovine viral diarrhoea virus
containing classical swine fever virus E2 gene. The virus is grown in porcine cells.
Challenge studies were conducted with the highly virulent reference strain CSFV
Koslov (genotype 1) and the moderately virulent, Roesrath strain (genotype 2,
Germany 2009). Limited studies in young pigs support protection against CSF1045
(genotype 2, Germany 2009) and CSF1047 (genotype 2, Israel 2009) field strains.
The recombinant vaccine virus has potential marker properties for use in DIVA
(differentiation between field virus infected and solely vaccinated animals).
Diagnostic tools targeted to detection of antibody responses could enable DIVA
strategies. Serological DIVA tools based on detection of CSFV antibodies other than
those raised against E2, such as Erns antibody detection should be able to
differentiate between antibody responses against Erns-BVDV after solely herd
vaccination with CP7_E2alf from responses against Erns-CSFV after natural field
CSFV infection.
DIVA efficiency depends on the performance of tests related to fitness for purpose in
outbreak situations. Serological DIVA concept has been shown in principle, while
actual DIVA tools remain to be tested on large panels of samples from emergency
vaccination in outbreak situations.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.